Quick Answer
GeneDx Holdings Corp. reported Total Assets of $523.71 million for the year ending 2025.
- GeneDx Holdings Corp. showed an increase of +24.9% in Total Assets from 2024 to 2025.
- This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $444.22 million | Q1 2022: $517.67 million | Q2 2022: $933.28 million | Q3 2022: $828.97 million | Q1 2023: $545.30 million | Q2 2023: $476.39 million | Q3 2023: $417.29 million | Q1 2024: $394.53 million | Q2 2024: $389.10 million | Q3 2024: $408.84 million | Q1 2025: $446.43 million | Q2 2025: $463.86 million | Q3 2025: $493.90 million.
- Over the full 9 years of available data (2020 to 2025), GeneDx Holdings Corp.'s Total Assets has grown by 108.1%.
- Historical annual values: Fiscal year 2025: $523.71 million | Fiscal year 2024: $419.38 million | Fiscal year 2023: $418.76 million | Fiscal year 2022: $490.94 million | Fiscal year 2021: $554.09 million | Fiscal year 2021: $603.36 million | Fiscal year 2021: $175.53 million | Fiscal year 2021: $219.30 million | Fiscal year 2020: $251.64 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: